Soros Fund Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Soros Fund Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-3,289,584	Closed	-$381M	–	283
2023 Q3	$381M	Sell	3,289,584 -2,217	-0.1%	-$238K	5.4%	2
2023 Q2	$339M	Hold	3,291,801	–	–	5.28%	2
2023 Q1	$359M	Buy	3,291,801 +433,300	+15%	+$47.9M	5.54%	1
2022 Q4	$325M	Buy	+2,858,501	New	+$237M	4.48%	1

Other funds holding HZNP

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.05B AUM 19.75% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Soros Fund Management's HZNP Position: Q4 2023 in Review

Soros Fund Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 3,289,584 shares — an estimated $381M sold.

Soros Fund Management first reported a position in HZNP in Q4 2022 and held it in 4 quarters. The position peaked at $381M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

Soros Fund Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Soros Fund Management sold 3,289,584 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $381M.
Soros Fund Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2022 and held it in 4 quarters.
Soros Fund Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $381M in Q3 2023.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Soros Fund Management's 13F filing for Q4 2023, filed 14 Feb 2024.